Results 161 to 170 of about 8,815 (184)
Some of the next articles are maybe not open access.
State of the art: balloon catheter technologies – drug-coated balloon
EuroIntervention, 2017Four decades after its introduction into clinical practice, coronary balloon angioplasty is still used during most coronary interventions. Conventional balloon angioplasty is frequently used to predilate complex or severe lesions and remains of major value to optimise the results of stent implantation.
Fernando, Alfonso, Bruno, Scheller
openaire +2 more sources
History of Drug-Coated Balloons
2019The advent of balloon angioplasty (BA) for the treatment of coronary artery disease was performed by Andreas Gruntzig in 1977 [1] (Fig. 1.1) and represented a breakthrough in the field of cardiology: by that time, we can say that modern interventional cardiology was born.
Dario Buccheri, Bernardo Cortese
openaire +1 more source
Advances on drug-coated balloons.
The Journal of cardiovascular surgery, 2010During the last decades considerable advances have been made in intravascular interventions for the treatment of coronary and peripheral arterial disease. However, long-term outcome remains an area of concern in many applications. Restenosis is still a challenge in endovascular medicine and has thus been referred to as the Achilles' heel of ...
G, Tepe +5 more
openaire +1 more source
Stent Use After Drug-Coated Balloons
2019Bailout stenting using bare-metal stents to treat a coronary dissection or residual stenosis after drug-coated balloon (DCB) inflation is associated with unfavorable clinical outcomes, while data regarding the feasibility and safety of using drug-eluting stents (DES) are limited.
Satoru Mitomo +4 more
openaire +1 more source
Drug-coated balloons: what is the evidence?
The Journal of cardiovascular surgery, 2016Having evolved at a rapid pace, the therapy options for percutaneous treatment of peripheral arterial disease in the lower limbs, especially percutaneous transluminal angioplasty in combination with stent-technology, are able to deliver a rate where at least 80% of the treated patients remain free from reintervention after the first years under ideal ...
L, Marques +2 more
openaire +2 more sources
Coronary Drug-Coated Balloon Angioplasty
JACC: Cardiovascular Interventions, 2023Róisín Colleran +2 more
openaire +1 more source
Dissection Management with Drug-Coated Balloons
2019In the “pre-stent era,” the immediate and midterm outcome of percutaneous transluminal coronary angioplasty (PTCA) was severely affected by restenosis, abrupt vessel closure, and coronary dissection. Regardless of the angiographic and morphological classification {Waller:1992tr}, the incidence of coronary dissection after PTCA has been reported ranging
Gaetano Di Palma, Bernardo Cortese
openaire +1 more source
Technical Insights on Drug-Coated Balloons
2019Interventional cardiology has witnessed several revolutionary developments over the last two decades leading to progressive changes in daily practice. The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES).
Marco Ferrone, Juan F. Granada
openaire +1 more source
Drug-Coated Balloon and Antithrombotic Therapy
2019In patients with lower extremity arterial disease (LEAD), antiplatelet therapy is used to prevent major adverse cardiac events (MACE) and major adverse limb events (MALE). Different strategies have been tested, involving the use of a single antiplatelet (SAPT) or a dual antiplatelet (DAPT) therapy, but their beneficial effect is still unclear, and ...
Arturo Alfani +3 more
openaire +1 more source